Next 10 |
2024-04-16 16:24:08 ET Summary HRTX has received approval for its supplemental New Drug Application for Zynrelef, allowing its use in more surgical procedures. The company has partnered with Crosslink Life Sciences to promote Zynrelef, which could further drive sales growth. T...
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City PR Newswire SAN DIEGO , April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on...
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire SAN DIEGO , March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig C...
2024-03-13 15:35:28 ET A California-based %Biotech company saw its shares soar on Wednesday, a day following the company’s Q4 earnings announcement. With analysts expecting a net loss of $0.16 per diluted share, %HeronTherapeutics (Nasdaq: HRTX) Q4 results came in at a net lo...
2024-03-13 13:18:36 ET More on Mid-day movers & stocks. Arq, Inc. (ARQ) Q4 2023 Earnings Call Transcript Heron Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Call Transcript Heron Therape...
2024-03-13 12:48:48 ET DENVER, Colo., Mar 13, 2024 ( 247marketnews.com )- Li-Cycle Holdings Corp. (NYSE: LICY ), Brera Holding ( NASDAQ:BREA ), Gaxos.ai Inc. (NASDAQ: GXAI ), The Beauty Health Company (NASDAQ: SKIN ), and Heron Therapeutics, Inc. (NASDAQ: HRTX ) are ...
2024-03-13 10:00:21 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...
2024-03-12 22:35:08 ET Heron Therapeutics, Inc. (HRTX) Q4 2023 Earnings Conference Call March 12, 2024 4:30 PM ET Company Participants Craig Collard – Chief Executive Officer Kevin Warner – Senior Vice President-Medical Affairs Strategy and Engagement ...
2024-03-12 16:05:59 ET More on Heron Therapeutics Heron Therapeutics Is Out Of Survival Mode Upcoming FDA Decision: Heron Therapeutics' ZYNRELEF SNDA Heron Therapeutics Gets Back On Track Heron Therapeutics Q4 2023 Earnings Preview Heron Therapeutics ...
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates PR Newswire 2023 oncology care franchise revenue was $107.9 million , exceeding full-year 2023 guidance ZYNRELEF ® achieved quarterly...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City PR Newswire SAN DIEGO , April 11, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that it will host an Investor Day on...
Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference PR Newswire SAN DIEGO , March 28, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that Craig C...
Tuesday, Heron Therapeutics Inc (NASDAQ:HRTX) reported a fourth-quarter 2023 EPS of $(0.07), beating the consensus of $(0.16). Sales incr...